Synthetic Biologics Inc. (SYN) |
|
0.5225 -0.002 (-0.29%)
|
02-14 15:58 |
|
Open: |
0.53 |
Pre. Close: |
0.524 |
|
High:
|
0.5321 |
Low:
|
0.5049 |
|
Volume:
|
193,383 |
Market Cap:
|
9M |
|
|
|
|
Synthetic Biologics Inc is a late-stage biotechnology company focused on developing gut microbiome therapeutics. It is also developing monoclonal antibody therapies for the treatment of pertussis. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.53 - 0.534 |
0.534 - 0.537 |
|
Low:
|
0.493 - 0.497 |
0.497 - 0.5 |
|
Close:
|
0.515 - 0.521 |
0.521 - 0.526 |
|
Technical analysis |
as of: 2020-02-14 4:32:55 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.67 One year: 0.74 |
| Support: |
Support1: 0.48 Support2: 0.40 |
| Resistance: |
Resistance1: 0.57 Resistance2: 0.63 |
| Pivot: |
0.54  |
| Moving Average: |
MA(5): 0.53 MA(20): 0.54
MA(100): 0.46 MA(250): 0.52 |
| MACD: |
MACD(12,26): 0.01 Signal(9): 0.01 |
| Stochastic oscillator: |
%K(14,3): 15.77 %D(3): 21.00 |
| RSI: |
RSI(14): 48.07 |
| 52-week: |
High: 0.85 Low: 0.37 Change(%): -19.6 |
| Average Vol(K): |
3-Month: 22228 10-Days: 24179 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.SYN has closed above bottom band by 28.5%. Bollinger Bands are 12% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2020-02-14
Smoking Gun? Chinese Scientist Finds "Killer Coronavirus Probably Originated From A Laboratory In Wuhan"
Smoking Gun? Chinese Scientist Finds "Killer Coronavirus Probably Originated From A Laboratory In Wuhan" The uncertainty and the debate over the origins of the coronavirus pandemic are growing with each passing day. One week after the White House asked scientists to finally investigate whether the Covid-19 virus was bio-engineered (i.e., created in a lab), none other than CNBC jumped on the bandwagon and echoing a similar question by Senator Tom Cotton - and of course, Zero Hedge - said " maybe the coronavirus was man made." All this is taking place as the mainstream press presses on with the popular theory that the virus emerged from the Huanan seafood market in Wuhan (we recently showed why this appears very unlikely) while branding anyone who suggests that the coronavirus might have originated as a bioweapon developed in a secretive Wuhan lab as deranged conspiracy theorist (a propaganda approach first popularized in the 1960s by the CIA to discredit controversial views ). Indeed, just today, the FT reported that Trevor Bedford, of the Fred Hutchinson Cancer Research Center in Seattle, "rubbished stories circulating on social media that Covid-19 was created at Wuhan Institute of Virology or elsewhere in China." Bedford is of course entitled to his opinion, which was only reinforced by the lack of any dissenting views from the scientific community, especially in "ground zero", China.
2020-02-13
Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020
ROCKVILLE, Md., Feb. 13, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report…
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE American |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
16.81 |
| Shares Float (M) |
16.30 |
|
% Held by Insiders
|
0.09 |
|
% Held by Institutions
|
12.87 |
|
Shares Short (K)
|
51 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
-1.783 |
|
Book Value (p.s.)
|
0.010 |
|
PEG Ratio
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-62.3 |
|
Return on Equity (ttm)
|
-146.1 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.920 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-13.56 |
|
Levered Free Cash Flow (M)
|
-7.96 |
Stock Valuations |
|
P/E
|
-0.29 |
|
P/E Growth Ratio
|
|
|
P/BV
|
52.24 |
|
P/S
|
|
|
P/CF
|
-0.65 |
Dividends & Splits |
|
Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Forward Dividend
|
|
|
Last Split Date
|
2018-08-12 |
|
Last Split Ratio
|
0.029 |
|
7 Binary Options
|
|
Your Ad Here
|
|
